TrialPath
Psoriasis · Phoenix

Psoriasis clinical trials in Phoenix

6 recruiting psoriasis studies within range of Phoenix. Click any trial for full eligibility criteria and contact info.

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

NCT02418442 · Rheumatic Joint Disease
Recruiting

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

Phase—
TypeObservational
Age21 Years
WhereBirmingham, Alabama, United States + 81 more
SponsorDuke University
▾Tap for details
Apply

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06857942 · Psoriasis, Overweight or Obesity
Recruiting

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

PhasePhase 4
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 37 more
SponsorEli Lilly and Company
▾Tap for details
Apply

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702 · Plaque Psoriasis
Recruiting

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

PhasePhase 2
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 38 more
SponsorOruka Therapeutics, Inc.
▾Tap for details
Apply

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

NCT07489885 · Psoriasis
Recruiting

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

PhasePhase 2
TypeInterventional
Age18 Years – 70 Years
WhereBirmingham, Alabama, United States + 19 more
SponsorInventisBio Co., Ltd
▾Tap for details
Apply

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453 · Plaque Psoriasis
Recruiting

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

PhasePhase 3
TypeInterventional
Age12 Years – 17 Years
WhereBirmingham, Alabama, United States + 136 more
SponsorBristol-Myers Squibb
▾Tap for details
Apply

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967 · Plaque Psoriasis
Recruiting

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

PhasePhase 3
TypeInterventional
Age40 Years
WhereBirmingham, Alabama, United States + 410 more
SponsorBristol-Myers Squibb
▾Tap for details
Apply